Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07061964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 131 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 179 to 181
  2. Re-verified, no change to tracked fields
  3. Study sites: 178 to 179
  4. Trial sites expanded: 165 → 177 locations
  5. Study sites: 164 to 165v127
  6. Study sites: 163 to 164v126
  7. Trial sites expanded: 160 → 163 locationsv125
  8. Study sites revised (160)v124 See this version in full on ClinicalTrials.gov ↗
  9. Study sites: 159 to 160v123
  10. Re-verified, no change to tracked fieldsv122
  11. Trial sites expanded: 148 → 157 locationsv121
  12. Study sites: 148 to 157v120
  13. Study sites: 146 to 148v119
  14. Study sites: 145 to 146v118
  15. Study sites: 144 to 145v117
  16. Study sites: 143 to 144v116
  17. Study sites: 142 to 143v115
  18. Study sites: 141 to 142v114
  19. Study sites: 140 to 141v113
  20. Trial sites expanded: 136 → 140 locations Site details revised at 1 of 140 sitesv112 Show 1 more changeShow less
    • Site details revised at 1 of 140 sites
  21. Site details revised at 1 of 140 sitesv111
  22. Study sites: 136 to 140v110
  23. Study sites: 134 to 136v109
  24. Site details revised at 1 of 134 sitesv108
  25. Site contacts updated at 1 of 134 sitesv107
  26. Study sites revised (134)v106 See this version in full on ClinicalTrials.gov ↗
  27. Site contacts updated at 1 of 134 sitesv105
  28. Study sites: 133 to 134v104
  29. Study sites: 132 to 133v103
  30. Study sites: 131 to 132v102
  31. Trial sites expanded: 128 → 131 locationsv101
  32. Study sites: 128 to 129v100
  33. 3 versions Re-verified since Apr 4, 2026, no change to tracked fieldsv97-v99
  34. Study sites: 127 to 128v96
  35. 2 versions Re-verified since Apr 1, 2026, no change to tracked fieldsv94-v95
  36. Study sites: 126 to 127v93
  37. Study sites: 125 to 126v92
  38. Study sites: 124 to 125v91
  39. Study sites: 123 to 124v90
  40. 6 versions Re-verified since Mar 18, 2026, no change to tracked fieldsv84-v89
  41. Study sites: 122 to 123v83
  42. Re-verified, no change to tracked fieldsv82
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neoadjuvant) to shrink or get rid of the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Photon beam radiation therapy is a type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator. The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Giving pembrolizumab in combination with radiation therapy after neoadjuvant chemotherapy may help prevent surgical removal of the bladder in patients with muscle invasive bladder cancer.
Trial Details
NCT Number NCT07061964
Lead Sponsor National Cancer Institute (NCI)
Conditions Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Enrollment 111 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov